Basics Actinium Pharmaceuticals, Inc Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's product portfolio includes Iomab-B and Actimab-A. IPO Date: January 1, 2003 Sector: Healthcare Industry: Biotech Market Cap: $51.47M Activated in VL: True Average Daily Range Avg Daily Range: $0.16 | 3.50% Avg Daily Range (30 D): $0.05 | 3.73% Avg Daily Range (90 D): $0.05 | 3.87% Institutional Daily Volume Avg Daily Volume: 1.07M Avg Daily Volume (30 D): .25M Avg Daily Volume (90 D): .42M Trade Size Avg Trade Size (Sh.): 470 Avg Trade Size (Sh.) (30 D): 159 Avg Trade Size (Sh.) (90 D): 207 Institutional Trades Total Inst.Trades: 45 Avg Inst. Trade: $1.85M Avg Inst. Trade (30 D): $.95M Avg Inst. Trade (90 D): $.95M Avg Inst. Trade Volume: .18M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $3.07M Avg Closing Trade (30 D): $3.9M Avg Closing Trade (90 D): $3.9M Avg Closing Volume: 288.69K         News May 25, 2025 @ 10:07 PM המועד האחרו×Å... Source: N/A May 25, 2025 @ 10:07 PM ATNM DEADLINE NOTICE: ROSEN, A HIGHLY RECOGNIZED L... Source: N/A May 21, 2025 @ 8:00 PM ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman... Source: Bronstein, Gewirtz & Grossman, Llc May 21, 2025 @ 12:00 AM ATNM INVESTOR ALERT: Kirby McInerney LLP Reminds A... Source: N/A May 19, 2025 @ 11:40 PM ROSEN, A TOP RANKED LAW FIRM, Encourages Actinium ... Source: N/A Financials   TTM Q1 2025 Q4 2024 Basic EPS $-1.47 $-.51 $-.21 Diluted EPS $-1.47 $-.51 $-.21 Revenue $ M $ M $ M Gross Profit $ $ $ Net Income / Loss $ -45.51M $ -15.94M $ -6.65M Operating Income / Loss $ -49.16M $ -16.64M $ -7.51M Cost of Revenue $ $ $ Net Cash Flow $ -11.15M $ M $ -5.75M PE Ratio     Splits Aug 11, 2020:   1:30